A genetically engineered virus is able to destroy cancer cells in animals and human tissue in laboratory tests, say U.S. scientists.
In a study published Friday in the Journal of Clinical Investigation, scientists at Jennerex Biotherapeutics in San Francisco said they had been able to harness the killer instinct of a virus used to vaccinate people against smallpox to make it zero in on tumours in both rabbits and mice.
Advertisement
Known as poxvirus, the lab-grown virus can spread extremely quickly within tissues in the body. The virus was engineered to attack certain cancer cells that have a specific protein, EGFR. The modified virus was then injected under the skin of lab animals with cancer tumours. Scientists found that the virus remained in the tumours for at least 10 days, showing that the hosts' antiviral immune responses did not destroy it. They also discovered that the normal tissues in the animals' bodies were not infected with the virus.
"Dramatic therapeutic effects against large primary tumours were demonstrated following systemic delivery," reads the report.
The researchers cautioned that repeated use of the virus in one patient as an anti-tumour agent may not work if a cancer patient has had previous exposure to the virus and developed antibodies to it.
![Powerful Lung Cancer Suppressor Identified]( "Powerful Lung Cancer Suppressor Identified")
Researchers have identified a gene LKB1 that acts as a tumour suppressor, and mutation in which leads to accelerated lung tumor growth.
However, they are buoyed by the fact that a repeat injection of the virus into animals six weeks after the initial injection decreased the size of the tumours in three of the four test subjects.
"Initial results indicate that an anti-tumour effect is feasible in previously immunized individuals," reads the report.
Tests on human samples in the lab, which included ovarian, muscle, pancreatic, breast, and lung cancer cells, also showed the virus killed cancerous cells rapidly.
Researchers believe the treatment holds promise for human cancers and suggest clinical trials in humans go ahead.
Source: Medindia
GPL/S
The researchers cautioned that repeated use of the virus in one patient as an anti-tumour agent may not work if a cancer patient has had previous exposure to the virus and developed antibodies to it.
Powerful Lung Cancer Suppressor Identified
Researchers have identified a gene LKB1 that acts as a tumour suppressor, and mutation in which leads to accelerated lung tumor growth.
Advertisement
However, they are buoyed by the fact that a repeat injection of the virus into animals six weeks after the initial injection decreased the size of the tumours in three of the four test subjects.
"Initial results indicate that an anti-tumour effect is feasible in previously immunized individuals," reads the report.
Tests on human samples in the lab, which included ovarian, muscle, pancreatic, breast, and lung cancer cells, also showed the virus killed cancerous cells rapidly.
Researchers believe the treatment holds promise for human cancers and suggest clinical trials in humans go ahead.
Source: Medindia
GPL/S
Development of the New Cancer Stem Cells can Facilitate Breast Cancer Research
Robert Weinberg member of the lab of whitehead has created breast cancer stem cells in a petridish which when injected in mice developed tumors that metastasized
Advertisement
 Molecular Pathway may Predict Chemotherapy Effectiveness in Lung Cancer PatientsA new research has found that physicians might be able predict which lung cancer patients will gain from chemotherapy drugs, through a common molecular pathway. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
In patients with breast cancer combination therapy had increased invasive disease-free survival compared to those who were treated with the hormone therapy alone.
An antibody treatment helped shrink tumors in some patients with bile duct cancers.
Comprehending the association between the gut microbiome and polyp growth sheds insights into potential screenings and treatments.
The first large-scale, collaborative, open analysis of genomic data provides a cloud-based resource for researchers looking for more comprehensive data on pediatric brain tumors.
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.